260 related articles for article (PubMed ID: 27855210)
1. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.
Leslie GJ; Wang J; Richardson MW; Haggarty BS; Hua KL; Duong J; Secreto AJ; Jordon AP; Romano J; Kumar KE; DeClercq JJ; Gregory PD; June CH; Root MJ; Riley JL; Holmes MC; Hoxie JA
PLoS Pathog; 2016 Nov; 12(11):e1005983. PubMed ID: 27855210
[TBL] [Abstract][Full Text] [Related]
2. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
3. Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41.
Maslennikova A; Kruglova N; Kalinichenko S; Komkov D; Shepelev M; Golubev D; Siniavin A; Vzorov A; Filatov A; Mazurov D
mBio; 2022 Feb; 13(1):e0358921. PubMed ID: 35073736
[TBL] [Abstract][Full Text] [Related]
4. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
6. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
7. Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor.
Liu L; Wen M; Zhu Q; Kimata JT; Zhou P
J Neuroimmune Pharmacol; 2016 Sep; 11(3):601-10. PubMed ID: 27155865
[TBL] [Abstract][Full Text] [Related]
8. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.
Stoddart CA; Nault G; Galkina SA; Thibaudeau K; Bakis P; Bousquet-Gagnon N; Robitaille M; Bellomo M; Paradis V; Liscourt P; Lobach A; Rivard ME; Ptak RG; Mankowski MK; Bridon D; Quraishi O
J Biol Chem; 2008 Dec; 283(49):34045-52. PubMed ID: 18809675
[TBL] [Abstract][Full Text] [Related]
9. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
10. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
Louis JM; Baber JL; Clore GM
Biochemistry; 2015 Nov; 54(45):6796-805. PubMed ID: 26506247
[TBL] [Abstract][Full Text] [Related]
11. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
Wilen CB; Wang J; Tilton JC; Miller JC; Kim KA; Rebar EJ; Sherrill-Mix SA; Patro SC; Secreto AJ; Jordan AP; Lee G; Kahn J; Aye PP; Bunnell BA; Lackner AA; Hoxie JA; Danet-Desnoyers GA; Bushman FD; Riley JL; Gregory PD; June CH; Holmes MC; Doms RW
PLoS Pathog; 2011 Apr; 7(4):e1002020. PubMed ID: 21533216
[TBL] [Abstract][Full Text] [Related]
12. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
13. Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
Zhao C; Princiotto AM; Nguyen HT; Zou S; Zhao ML; Zhang S; Herschhorn A; Farrell M; Pahil K; Melillo B; Sambasivarao SV; Abrams C; Smith AB; Madani N; Sodroski J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391272
[TBL] [Abstract][Full Text] [Related]
14. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
[TBL] [Abstract][Full Text] [Related]
16. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
[TBL] [Abstract][Full Text] [Related]
17. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
18. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
19. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
20. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
